Biogen Inc and MedRhythms have entered into a license agreement to develop and commercialize MR-004, an investigational prescription digital therapeutic for the potential treatment of gait deficits in multiple sclerosis (MS). The collaboration combines MedRhythms’...
CB Insights has named MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, to its third annual Digital Health 150, which...
MedRhythms announces reportedly a first-of-its-kind partnership with Universal Music Group (UMG) that provides MedRhythms with access to UMG’s music catalog to provide prescription music to patients with neurological conditions. MedRhythms’ platform is based on...
MedRhythms announces the closing of a $25 million Series B financing round co-led by Morningside Ventures and Advantage Capital, with participation from existing investor Werth Family Investment Associates. It has raised a total of $34 million in gross proceeds from...
MedRhythms, a digital therapeutics company building direct stimulation solutions that use clinical-grade sensors, software and music to help restore function lost to neurologic disease or injury, announces the launch of a clinical trial that will study MR-010,...
